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Background: Lymph	 node	 metastasis	 (LNM)	 has	 been	 established	 as	 a	 criti-
cal	 risk	 factor	 for	 prognosis	 in	 intrahepatic	 cholangiocarcinoma	 (ICC).	 The	








confirmed	 in	 90	 patients	 (40%).	 Prognosis	 was	 poorer	 for	 patients	 with	 LNM	
(median	survival,	16.9 months)	than	for	those	without	(57.2 months;	P < .0001).	
One-	,	3-	,	and	5-	year	overall	survival	rates	(OS)	were	comparable	among	LND+	
(81.6%,	 48.0%,	 and	 37.5%,	 respectively)	 and	 LND–	 groups	 (81.6%,	 55.4%,	 and	
44.6%,	respectively).	However,	advanced	tumor,	as	characterized	by	larger	tumor,	
multinodular	 lesions,	 and	 serosal	 invasion,	 was	 significantly	 more	 frequent	 in	
the	LND+	group	than	in	the	LND–	group.	After	IPTW	adjusting	for	imbalances,	
1-	,	3-	,	and	5-	year	OS	were	better	in	the	LND+	group	(83.5%,	52.2%,	and	42.8%,	




2 |   UMEDA et al.
1 |  INTRODUCTION
Intrahepatic	cholangiocarcinoma	(ICC)	is	a	primary	liver	
cancer	with	incidence	second	only	to	hepatocellular	car-
cinoma.	ICC	arises	 from	the	epithelial	cells	of	 the	 intra-
hepatic	 bile	 ducts,	 as	 either	 small	 intrahepatic	 ductules	
or	large	intrahepatic	ducts	proximal	to	the	bifurcation	of	
the	hepatic	ducts.1	ICC	may	occur	in	patients	with	normal	
liver	 or	 with	 underlying	 liver	 disease.2	 In	 either	 clinical	
context,	 the	 pathology	 is	 usually	 classified	 as	 adenocar-
cinoma,	 although	 mixed	 hepatocellular	 cholangiocar-
cinoma	 also	 occurs,	 especially	 against	 a	 background	 of	


















of	 lymph	 node	 dissection	 (LND)	 at	 the	 time	 of	 surgery	
remains	 controversial,	 with	 some	 centers	 considering	
this	procedure	standard,	whereas	other	surgeons	perform	




therapeutic	 benefits	 from	 lymphadenectomy	 does	 not	
seem	sufficient,	and	consensus	is	 lacking	about	whether	
LND	should	be	routinely	performed.10
The	 present	 study	 aimed	 to	 identify	 the	 clinical	 fea-
tures	 of	 LNM,	 including	 incidence	 of	 LNM,	 according	
to	 tumor	 localization,	 and	 to	 confirm	 the	 significance	
of	systematic	LND	as	a	therapeutic	option	with	curative	
intent.
2 |  METHODS
2.1 | Study subjects
In	 this	 multicenter	 retrospective	 study,	 study	 subjects	
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resection	 (residual	 tumor,	 peritoneal	 dissemination,	 or	
positive	surgical	margin	[n = 13]);	or	(b)	morphologically	
evident	 intraductal	 growth	 (n  =  18);	 or	 (c)	 insufficient	
medical	records	for	statistical	analysis	as	described	below	
(n = 57).	After	excluding	those	individuals	who	met	the	
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defined	as	hilar	 type,	whereas	 the	other	 tumors	without	
these	contacts	were	defined	as	peripheral	type	ICC.
2.2 | Lymph node dissection
Therapeutic	 LND	 was	 defined	 as	 systematic	 lymphad-
enectomy	 including	 the	 regional	 lymphatic	 basin.	 Sites	
of	 lymph	 node	 were	 categorized	 according	 to	 lymphatic	
station	 around	 the	 peri-	hilum,	 pancreatic	 head,	 celiac	
axis,	 and	 lesser	 curvature	of	 the	 stomach.14	With	 regard	
to	LND,	normal	LND	was	defined	as	dissection	of	lymph	




and	 posterior	 pancreas.	 Particularly	 with	 left	 peripheral	
ICCs,	LND	was	extended	to	the	celiac	nodes	and	gastro-	
cardiac	nodes	around	the	lesser	curvature	of	the	stomach	





2.3 | Statistical analysis
All	statistical	analyses	were	performed	using	STATA/MP4	
















the	 intent	of	 surgeons	or	 institutional	policy	could	have	
been	 present.	 To	 adjust	 for	 these	 imbalances	 in	 back-
ground	 characteristics,	 the	 inverse	 probability	 of	 treat-
ment	weighting	(IPTW)	procedure	was	performed,	where	
weights	were	 the	 inverse	of	 the	probabilities	assigned	to	
the	actual	treatment	group,	estimated	based	on	the	base-
line	 demographic	 and	 clinical	 characteristics	 of	 patients	
(age,	gender,	body	mass	 index,	etiology	 [hyperlipidemia,	
diabetes],	preoperative	levels	of	CEA	and	CA19-	9,	tumor	






aforementioned	 clinical	 variables	 was	 judged	 as	 inade-
quate	 for	 IPTW	procedure.	Thus,	as	described	above,	57	
patients	were	excluded	from	the	entire	primary	cohort.
After	 confirming	 the	 hypothesis	 of	 proportional	 haz-









2.4 | Ethics statement
This	 study	 was	 approved	 by	 the	 Ethics	 Committee	 of	
Okayama	 University	 Hospital	 (number	 1701-	026).	 The	
need	to	obtain	written	consent	was	waived	because	of	the	
retrospective	nature	of	the	study.
3 |  RESULTS
3.1 | Incidence of lymph node 
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was	mass-	forming	(MF)	type	(76%),	followed	by	MF	and	
periductal-	infiltrating	(PI)	type	(12%),	and	PI	type	(11%).	
Regarding	 surgical	 procedures,	 approximately	 90%	 of	
patients	 underwent	 major	 hepatectomy.	 LND	 was	 per-






the	 training	 institutions	 B,	 and	 65%	 (13/20)	 in	 the	 non-	
certified	 training	 institutions,	 respectively	 (P =  .133).	 In	
other	words,	high-	volume	centers	 tended	to	perform	ex-
tended	 LND.	 Of	 the	 224	 patients	 who	 underwent	 LND,	
LNM	were	pathologically	confirmed	in	90	patients	(40%)	
(Table 1).	The	entire	patient	 cohort	was	divided	 into	an	
LND+	 group	 (n  =  224)	 and	 an	 LND–	 group	 (n  =  86).	
Although	 baseline	 characteristics	 of	 patients	 with	 and	
without	 LND	 were	 comparable,	 more	 advanced	 tumors	
were	seen	in	the	LND+	group.	That	is,	the	LND+	group	
showed	 significantly	 greater	 tumor	 size	 (LND+	 group,	
4.5 cm	vs	LND−	group,	3.3 cm;	P = .002)	and	higher	fre-
quencies	 of	 multinodular	 lesions	 (LND+	 group,	 22.8%	
vs	 LND−	 group,	 10.5%;	 P  =  .010)	 and	 serosal	 invasion	
(LND+	 group,	 43.3%	 vs	 LND−	 group,	 26.7%;	 P  =  .020)	
than	 the	 LND−	 group.	 LND	 was	 performed	 more	 fre-










value	 of	 118  U/mL,	 pathological	 invasion	 of	 the	 serosa,	
and	 moderate	 or	 poor	 differentiation	 were	 determined	
as	significant	risk	factors	for	LNM	(Table 2).	In	terms	of	
frequent	 metastatic	 stations	 of	 LNM,	 some	 differences	
were	 identified	 between	 tumor	 localizations	 (Figure  1).	
In	 particular,	 hilar	 and	 left	 peripheral	 ICCs	 were	 likely	
to	 spread	 to	 gastro-	cardiac	 and	 celiac	 nodes	 beyond	 the	








In	 survival	 analysis,	 patients	 with	 LNM	 showed	
poorer	 prognosis	 than	 those	 without	 LNM	 (median	
survival	 time	 [MST],	 16.9	 vs	 57.2  months,	 respectively;	
P  <  .0001)	 (Figure  2A).	 Regarding	 tumor	 location,	 hilar	
ICC	showed	poorer	prognosis	than	peripheral	ICC	(MST,	
24.9	vs	57.3 months,	respectively;	P = .0001)	(Figure 2B).	
Concerning	 the	 therapeutic	 value	 of	 LND,	 MST	 strat-
ified	 by	 LND	 was	 34.1  months	 in	 the	 LND+	 group	 and	
46.5  months	 in	 the	 LND–	 group.	 Similarly,	 1-	,	 3-	,	 and	
5-	year	 OS	 rates	 were	 comparable	 among	 patients	 in	 the	
LND+	group	(81.6%,	48.0%,	and	37.5%,	respectively)	com-
pared	 to	 the	 LND−	 group	 (81.6%,	 55.4%,	 and	 44.6%,	 re-
spectively;	P = .747)	(Figure 3A).	The	prognostic	impact	
of	 LND	 was	 not	 significant	 (hazard	 ratio	 [HR]  =  1.06;	





3.2 | Survival impact of LND among 
patient- adjusted baseline characteristics 
by IPTW
The	IPTW	procedure	was	performed	to	adjust	for	imbal-
ances	 in	 these	 retrospective	 settings.	After	 IPTW	adjust-
ment,	the	sum	of	weights	was	310.2	in	the	LND+	group	
and	286.4	 in	 the	LND–	group.	After	 IPTW	adjusting,	no	
variables	 other	 than	 bile	 duct	 resection	 (P  =  .037)	 and	
duration	 of	 operation	 (P  =  .001)	 remained	 significantly	
unbalanced	(Table 1).	Although	these	two	variables	were	
still	 significantly	 different	 after	 IPTW	 adjusting,	 the	 dif-
ference	 between	 groups	 was	 decreased.	 These	 results	
suggested	 that	 the	 balance	 of	 covariates	 was	 sufficiently	
improved	by	IPTW.	As	a	result,	background	profiles	and	
tumor-	specific	 characteristics	 of	 patients	 with	 and	 with-
out	LND	were	similar.
In	 the	 IPTW-	adjusted	 cohort,	 MST	 was	 longer	 in	 the	







With	 regard	 to	 the	 extent	 of	 LND,	 MSTs	 were	
52.0 months	for	normal	LND	and	31.2 months	for	extended	
LND.	One-	,	3-	,	and	5-	year	OS	rates	with	normal	LND	were	
comparable	 to	 those	 with	 extended	 LND	 (normal	 LND,	
92.8%,	56.0%,	and	39.8%,	vs	extended	LND,	81.1%,	45.0%,	
and	36.6%,	respectively;	Figure 3D).	A	significant	positive	
prognostic	 impact	 was	 seen	 for	 normal	 LND	 (vs	 LND−,	
HR  =  0.51,	 95%CI  =  |0.29|–	|0.90|,	 P  =  .020).	 Although	
extended	LND	tended	to	show	positive	therapeutic	value	

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ICC	 showed	 significant	 benefit	 from	 LND	 (vs	 LND−,	
HR = 0.45,	95%CI = |0.25|–	|0.83|,	P = .011).	On	the	other	
hand,	 peripheral	 ICC	 displayed	 no	 therapeutic	 benefit	
from	LND	(Table 3,	Figure	S2).
Concerning	 long-	surviving	 cases,	 12	 patients	 with	
pathologically	 confirmed	 LNM	 survived	 for	 more	 than	
5  years	 after	 resection.	 Notably,	 all	 patients	 had	 under-
gone	 major	 hepatectomy	 with	 LND.	 Although	 nine	 pa-
tients	 showed	 recurrence	 at	 various	 sites,	 their	 survival	
was	 through	 treatment	 under	 a	 multidisciplinary	 ap-
proach	involving	resection	of	recurrences,	chemotherapy,	
and	radiation	therapy	(Table 4).






as	 a	 negative	 prognostic	 factor.5,9,10,15,16	 ICC	 with	 LNM	
could	be	judged	as	an	“unresectable	disease”	based	on	the	
systemic	spread	of	the	cancer	according	to	the	guidelines	
of	 the	 International	 Liver	 Cancer	 Association.17	 Under	
such	conditions	of	tumor	biology,	routine	LND	with	cura-
tive	 intent	 has	 been	 widely	 performed	 as	 part	 of	 radical	
hepatic	resection.	However,	 few	reports	have	referred	to	
the	 positive	 prognostic	 value	 of	 LND,	 and	 survival	 rates	
have	 been	 reported	 as	 30%–	40%	 at	 5  years	 postopera-
tively.15,18,19	In	particular,	LND	has	appeared	to	show	no	
prognostic	 impact	when	 the	 lymph	node	 involvement	 is	
not	clinically	apparent.	Furthermore,	Li	et	al	reported	that	
the	rate	of	recurrence	in	regional	lymph	nodes	was	only	
4.9%.	 In	 other	 words,	 the	 prognostic	 value	 of	 LND	 has	
seemed	limited.20
However,	 such	 statements	 have	 been	 gathering	 some	
opposition.	For	a	start,	the	extent	of	LND	has	differed	be-
tween	reports.	Further,	the	presence	of	bias	in	background	
T A B L E  2  Logistic	regression	analysis	to	examine	risk	factors	for	lymph	node	metastasis
Variables
Univariable analysis Multivariable analysis
Number
Odds 
ratio 95% CI P- value
Odds 
ratio 95% CI P- value
Background	factor
Sex Male	vs	Female 126	vs	98 0.61 0.35-	1.03 .068 ー ー ー
Age ≥	60	vs	<60 199	vs	25 2.98 1.15-	9.24 .022 2.88 0.88-	11.51 .081
Body	mass	index ≥	20	vs	<20 165	vs	59 1.96 1.04-	3.80 .035 1.70 0.76-	3.92 .193
Hypertension present	vs	absent 86	vs	138 1.21 0.69-	2.10 .503 ー ー ー
Hyperlipidemia present	vs	absent 40	vs	184 0.85 0.40-	1.73 .661 ー ー ー






165	vs	59 0.42 0.22-	0.75 .004 0.29 0.12-	0.63 .002
Tumor	size	(cm) ≥	4	vs	4	< 132	vs	92 1.47 0.85-	2.56 .167 ー ー ー








109	vs	48 1.91 0.93-	4.05 .075 ー ー ー
CEA	(ng/mL) ≥	6.5	vs	<6.5 52	vs	172 2.07 1.10-	3.90 .023 0.91 0.41-	1.93 .813
CA19-	9	(U/mL) ≥	118	vs	<118 85	vs	139 5.56 3.09-	10.18 <.0001 6.32 3.10-	13.52 <.0001
Pathology
Vascular	invasion present	vs	absent 128	vs	96 1.05 0.60-	1.83 .865 ー ー ー
Serosa	invasion present	vs	absent 97	vs	127 1.81 1.04-	3.14 .033 2.21 1.11-	4.48 .022
Grading mod/por	vs	well 163	vs	61 2.37 1.20-	4.94 .012 4.04 1.71-	10.30 .001
Note: *including	mass-	forming + periductal-	infiltrating.
Abbreviations:	CA19-	9,	carbohydrate	antigen	19-	9;	CEA,	carcinoembryonic	antigen.
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F I G U R E  1  Incidence	of	lymph	node	metastasis	and	frequent	lymph	node	stations	according	to	tumor	localization
F I G U R E  2  Overall	survival	curves	after	surgery	in	the	crude	cohort.	(A)	Status	of	pathological	lymph	node	metastasis:	pathological	N+	
versus	N–	vs	Nx	(no-	lymph	node	dissection).	(B)	Tumor	localization:	hilar	vs	peripheral
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factors	 and	 institutional	 policy	 or	 surgeon	 preferences	
cannot	be	ignored,	given	the	retrospective	settings.	In	this	
context,	Kim	identified	a	prognostic	impact	of	LND	using	
a	 propensity	 score-	matching	 method.21	 In	 this	 report,	
radical	 surgery	 including	 adequate	 LND	 contributed	 to	
improved	oncological	outcomes	for	ICC	on	the	basis	of	a	





T A B L E  3  Sub-	analysis	and	Sub-	group	analysis	for	prognostic	impact	of	LND	before	and	after	IPTW	adjustment
Variables
Before IPTW adjustment After IPTW adjustment
Hazard 
ratio 95% CI P- value
Hazard 
ratio 95% CI P- value
Main	analysis
LND+ vs	LND–	 1.06 0.74-	1.51 .747 0.58 0.39-	0.84 .005
Sub-	analysis	(Extent	of	LND)
Extended	LND+ vs	LND–	 1.07 0.75-	1.55 .700 0.67 0.45-	1.02 .063
Normal	LND+ vs	LND–	 1.00 0.61-	1.66 .990 0.51 0.29-	0.90 .020
Sub-	group	analysis	(Tumor	location)
Hilar:	LND+ vs	LND–	 0.65 0.35-	1.24 .192 0.45 0.25-	0.83 .011
Peripheral	left	side:	LND+ vs	LND–	 0.96 0.53-	1.75 .894 0.86 0.37-	2.00 .729
Peripheral	right	side:	LND+ vs	LND–	 0.97 0.49-	1.92 .938 0.52 0.25-	1.10 .089
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propensity	score-	matching	method,	in	a	study	that	mainly	
included	 morphological	 intraductal-	growth	 type	 and	 PI	
type	 tumors.	 In	 addition,	Vitale	 reported	 that	 the	 thera-
peutic	benefit	of	LND	could	be	calculated	as	5.46 months	
in	a	survival	benefit	simulation	analysis	using	the	SEER	
database.22	 In	 terms	 of	 recent	 trends,	 the	 proportion	 of	




This	 multi-	institutional	 study	 focused	 on	 identifying	







a	 randomized	 controlled	 study	 would	 be	 invaluable	 but	
has	not	been	realistic	due	to	the	relative	rarity	of	ICC	and	
the	commonly	accepted	surgical	strategy	of	LND.	Initially,	










with	 a	 medium	 probability	 of	 receiving	 LND.	 IPTW,	 on	
the	other	hand,	estimates	LND	by	weighting.	Therefore,	
it	 is	possible	 to	estimate	 the	effect	of	LND	on	the	entire	
patient	 population.	Thus,	 there	 is	 a	 difference	 in	 the	 ef-
fect	 that	 PSM	 and	 IPTW	 are	 trying	 to	 estimate.25	 Based	
































#7,	12 +/+ GEM + CDDP -	 -	 5 years,	alive
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Lung
Chemotherapy 5.3 years,	dead
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Chemotherapy
5.5 years,	dead
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hemihepatectomy
− -	 #1,	3,	8,	12 #1,	12 +/+ GEM 1 year,	LN Resection 5.9 years,	alive
7 Female/68 3.0 Hilar PI Solitary 684.0 Left	
hemihepatectomy
+ -	 #8,	12 #12 −/− -	 3.6 years,	LN Chemotherapy 6 years,	dead
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on	 this	background,	 the	 IPTW	method	appeared	 to	be	a	
more	suitable	analysis	 than	a	propensity	score-	matching	
method.	 The	 clinical	 relevance	 of	 LND	 was	 confirmed	
by	 IPTW	 analysis,	 showing	 a	 positive	 prognostic	 impact	
(HR = 0.58,	P = .005).	In	addition	to	these	results,	the	fact	













of	 extended	 LND	 and	 because	 postoperative	 morbidity	
is	 linked	 to	 the	 unfeasibility	 of	 adjuvant	 chemotherapy.	
Following	 the	 generally	 poor	 outcomes	 of	 surgery	 for	
ICCs,	 adjuvant	 therapy	 has	 recently	 tended	 to	 receive	
strong	consideration	for	further	improvement	of	surgical	
prognosis	for	ICC.	While	the	clinical	benefits	of	adjuvant	





of	 LNM	 and	 advanced	 tumor.27	 From	 this	 perspective,	
LND	is	necessary	for	identifying	nodal	status.
By	 mapping	 LNM-	stratified	 tumor	 localizations,	 the	
targets	of	systematic	LND	could	be	clarified.	Most	lymph	
vessels	of	the	liver	flow	in	retrograde	along	the	Glissonean	
pedicle	 and	 into	 lymph	 nodes	 along	 the	 hepatoduodenal	
ligament.	The	direction	of	LNM	in	extra-	hepatic	sites	then	
depends	on	 the	 location	of	 the	 ICC	primary.28	 In	our	 re-
sults,	hilar	ICCs	showed	the	highest	ratio	of	LNM,	at	44%,	
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followed	 by	 left	 peripheral	 and	 right	 peripheral	 ICCs,	 as	
reported	by	previous	studies.	Hilar	ICC	reportedly	shows	
a	greater	tendency	to	metastasize	to	the	lymph	nodes	than	




of	 lymphatic	 spread	 into	 celiac	 nodes	 and	 gastro-	cardiac	
























Although	 the	 significance	 of	 lymph	 node	 dissection	
has	been	debated	for	a	long	time	and	should	be	established	
by	randomized	controlled	trials	(RCTs),	it	is	difficult	to	do	
so	 in	 practice	 and	 the	 impact	 can	 only	 be	 estimated	 by	





A	 well-	designed	 prospective	 study	 remains	 necessary	 to	
more	fully	address	this	issue.
5 |  CONCLUSIONS
While	it	has	been	and	will	continue	to	be	difficult	to	con-
duct	 RCTs	 to	 prove	 the	 efficacy	 of	 LND	 for	 ICC,	 this	 is	
the	 first	 report	 to	 demonstrate	 the	 efficacy	 of	 LND	 for	
ICC	 using	 sufficient	 clinicopathological	 data	 on	 LNM	
and	novel	statistical	method	of	IPTW.	In	addition	to	the	
essential	 role	 of	 LND	 for	 accurate	 staging	 to	 assist	 in	
decision-	making	regarding	adjuvant	therapy,	LND	could	
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